Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Notes Payables (2023 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Notes Payables for 3 consecutive years, with $6.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Notes Payables changed N/A to $6.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.0 million, a N/A change, with the full-year FY2023 number at $6.7 million, changed N/A from a year prior.
  • Notes Payables was $6.0 million for Q3 2025 at Werewolf Therapeutics, up from $2.4 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $11.7 million in Q1 2024 to a low of $1.7 million in Q3 2023.
  • A 3-year average of $5.7 million and a median of $6.0 million in 2025 define the central range for Notes Payables.